GWPH News and Press, GW Pharmaceuticals Plc From 11/26/19

The share prices of several notable marijuana stocks are slumping on a new warning about cannabidiol (CBD) from the U.S. Food and Drug Administration (FDA). Yesterday the health industry regulator issued a new "consumer update" regarding CBD, the nonpsychoactive ingredient in cannabis that pr...

Despite the positive momentum made in legalizing cannabis in the United States over the last 5 years, we may ironically be right back where we started in terms of cannabis prohibition in 1937. The Marijuana Tax Act, which became law in the US on October 1 of that year, was designed to effect...

A medical research cannabis company has obtained a critical approval for its investigation of a drug to treat uncontrolled pain in advanced cancer patients. On Monday (November 25), Tetra Bio-Pharma (TSXV: TBP ,OTCQB:TBPMF) informed its shareholders the US Food and Drug Administration (FDA...

Let's face it: Marijuana stocks  are struggling. Last week, several of the top pot companies -- including the two largest,  Aurora Cannabis and Canopy Growth , reported their quarterly results, and they performed so badly that the ensuing response by the market was a bloodbath. S...

After breaking support in June for many more immediate bullish setups in the sector, a larger correction consumed most names like a serious case of the munchies. But we have good confluence for a new significant bottom to be forming and are getting some decent pops off recent lows. In the foll...

A few developments in the marijuana industry have kept shorts of cannabis stocks at bay, a new report from research firm S3 Analytics stated. On Wednesday (November 20), the firm published a study indicating short sellers of the marijuana public market were down US$272 million during the tra...

GW Pharmaceuticals (GWPH) produced excellent Q3 results recently. The result of this was a steep decline in the stock price. This was partly due to unrealistic expectations of the expected revenue in some quarters. The company had specifically warned against this at the Q2 analyst earnings c...

As North American cannabis companies battle for supremacy,  GW Pharmaceuticals  (NASDAQ: GWPH) , an ocean away, is benefiting from more and more opportunities arising in Europe. Earlier this year, the company received  approval  in dozens of European countries for use of its...

GW Pharmaceuticals PLC (GWPH) Stifel Healthcare Broker Conference Call November 20, 2019, 13:15 ET Company Participants Steve Schultz - VP, IR Conference Call Participants Paul Matteis - Stifel Nicolaus Presentation Paul Matteis Thank you very much. For those on the w...

In case you missed it, last week was the earnings free-for-all in the cannabis industry that Wall Street and investors had patiently waited for. Unfortunately, things did not go as planned. Although it was a well-known fact that Canadian pot stocks have been hit hard by supply issues, and U.S...